Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAIRE: Combining Epigenetic and Immune Therapy to Beat Cancer
2023-509501-72-00Phase 2Completed
- Sponsor
- Institut Bergonié
- Start
- Oct 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab and tazemetostat in pancreatic cancer (PC), colorectal cancer (CRC), Nonhematologic neoplasms and 2 more (4 cohorts), sponsored by Institut Bergonié. Primary endpoints: Disease control rate within 24 weeks (Cohort A: pancreatic cancer), Disease control rate within 24 weeks (Cohort B: colorectal cancer non–MSI-H/MMR-deficient) and 2 more. Started Oct 2024; status: completed.
02
Drugs
durvalumabtazemetostat
03
Conditions
pancreatic cancer (PC)colorectal cancer (CRC)Nonhematologic neoplasmssoft tissue sarcoma (STS)solid tumor
Beyond the preview
Go deeper on 2023-509501-72-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509501-72-00.